Investments
10Portfolio Exits
4Partners & Customers
10About OPKO Health
OPKO Health, formerly eXegenics, is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging discovery, development, and commercialization expertise. The company intends to leverage global commercialization expertise to pursue acquisitions of commercial businesses that will both drive growth and provide geographically diverse sales and distribution opportunities.

Want to inform investors similar to OPKO Health about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing OPKO Health
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find OPKO Health in 3 Expert Collections, including Vitamin & Supplement Startups.
Vitamin & Supplement Startups
237 items
Medical Devices
295 items
Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA
Health Monitoring & Diagnostics
702 items
Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting
Latest OPKO Health News
Jan 17, 2023
Major Players MDXHEALTH, F. Hoffmann-La Roche Ltd, Genomic Health, Inc., Siemens Healthcare GmbH, Abbott, Metamark Genetics, Inc., HUMASIS, FUJIREBIO, OPKO Health, Inc., bioMérieux, Inc., Siemens Healthcare GmbH, Diasorin S.P.A. among others. Segmentation Analysis Preliminary is expected to be the fastest-growing segment in 2022. The test type segment includes confirmatory and preliminary. The preliminary segment is expected to witness the highest growth rate during the forecast period. As prostate cancer is on the rise over the forecast period in the region, it is boosting the demand for the preliminary test segment. The American Institute for Cancer Research has noted that PSA screening has helped diagnose and treat early cancers, leading to an increase in survival rates. PSA tests detect small, unrecognized tumours which may or may not progress to advanced stages. Hospital-associated laboratories are expected to be the fastest-growing segment in 2022. The end-user segment includes cancer research institutes, hospital-associated laboratories and independent diagnostics laboratories. The hospital-associated laboratories segment is expected to witness the highest growth rate during the forecast period. In the global prostate cancer diagnostics market, hospital associated laboratories are expected to take the majority share during the forecast period because of an increase in prostate cancer cases. In the forecast period, the market growth will be driven by rising disease prevalence and technological advancements. Regional Analysis The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the biomarkers market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North American region witnessed a major share. It is expected that North America will dominate the market due to factors such as increased prostate cancer prevalence, increased awareness, and the increasing number of research and development companies in this region. Prostate cancer cases are rising, creating huge opportunities for market players, and many are developing new and effective treatments. Country Analysis Germany Germany's prostate cancer diagnostics market size was valued at USD 0.83 billion in 2022 and is expected to reach USD 0.85 billion by 2030, at a CAGR of 13.5% from 2023 to 2030. Innovative products, growing awareness and government initiatives are all contributing to the growth of the prostate cancer diagnostics market. China China’s prostate cancer diagnostics market size was valued at USD 0.33 billion in 2022 and is expected to reach USD 0.92 billion by 2030, at a CAGR of 13.7% from 2023 to 2030. As China has a large population and therefore has more tests per capita than any other country in the region, China is expected to dominate the Asia-Pacific prostate cancer diagnostics market. India India's prostate cancer diagnostics market size was valued at USD 0.25 billion in 2022 and is expected to reach USD 0.69 billion by 2030, at a CAGR of 13.6% from 2023 to 2030. The availability of a wide range of products, adjustments in consumption patterns, improved lifestyles, and an increase in personal care spending are anticipated to contribute to the growth of the nail industry in the future. The popularity of nail polish and nail art has increased in the country due to a growing party culture as well as a variety of festivals and functions. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of this market is mainly driven owing to the increase due of the rising cases of cancer and cardiovascular diseases, propelling the growth of the market across the countries. Buy Now Full Report @ https://greyviews.com/checkout/334/single_user_license Contact Us
OPKO Health Investments
10 Investments
OPKO Health has made 10 investments. Their latest investment was in HealthSnap as part of their Series B on November 11, 2021.

OPKO Health Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
11/12/2021 | Series B | HealthSnap | $5M | Yes | 6nine26, Florida Funders, MacDonald Ventures, OPKO Health, StrongPath, and W5 Group | 2 |
8/2/2017 | Series C | Eloxx Pharmaceuticals | $8M | No | 2 | |
6/26/2017 | Series B - II | Eloxx Pharmaceuticals | $6M | Yes | OPKO Health, and Pontifax | 1 |
8/23/2016 | Corporate Minority | |||||
10/10/2013 | Corporate Minority |
Date | 11/12/2021 | 8/2/2017 | 6/26/2017 | 8/23/2016 | 10/10/2013 |
---|---|---|---|---|---|
Round | Series B | Series C | Series B - II | Corporate Minority | Corporate Minority |
Company | HealthSnap | Eloxx Pharmaceuticals | Eloxx Pharmaceuticals | ||
Amount | $5M | $8M | $6M | ||
New? | Yes | No | Yes | ||
Co-Investors | 6nine26, Florida Funders, MacDonald Ventures, OPKO Health, StrongPath, and W5 Group | OPKO Health, and Pontifax | |||
Sources | 2 | 2 | 1 |
OPKO Health Portfolio Exits
4 Portfolio Exits
OPKO Health has 4 portfolio exits. Their latest portfolio exit was Eloxx Pharmaceuticals on December 22, 2017.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
12/22/2017 | Reverse Merger | 2 | |||
Date | 12/22/2017 | |||
---|---|---|---|---|
Exit | Reverse Merger | |||
Companies | ||||
Valuation | ||||
Acquirer | ||||
Sources | 2 |
OPKO Health Acquisitions
16 Acquisitions
OPKO Health acquired 16 companies. Their latest acquisition was ModeX Therapeutics on May 09, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
5/9/2022 | Acquired | 2 | ||||
6/30/2016 | Acquired | 1 | ||||
5/5/2015 | Acquired | 2 | ||||
5/22/2014 | ||||||
1/8/2014 |
Date | 5/9/2022 | 6/30/2016 | 5/5/2015 | 5/22/2014 | 1/8/2014 |
---|---|---|---|---|---|
Investment Stage | |||||
Companies | |||||
Valuation | |||||
Total Funding | |||||
Note | Acquired | Acquired | Acquired | ||
Sources | 2 | 1 | 2 |
OPKO Health Partners & Customers
10 Partners and customers
OPKO Health has 10 strategic partners and customers. OPKO Health recently partnered with Pfizer on February 2, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
2/15/2022 | Licensee | United States | In 2014 , Pfizer and OPKO Health , Inc. entered into a worldwide agreement for the development and commercialization of NGENLA for the treatment of GHD . | 2 | |
9/24/2021 | Licensee | United States | In 2014 , Pfizer and OPKO Health , Inc. entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD . | 2 | |
9/14/2021 | Licensee | United States | SHANGHAI and MIAMI , Sept. 14 , 2021 -- LeaderMed Group , a pharmaceutical development company with operations based in Asia , and OPKO Health , Inc. , a diversified healthcare company focused on diagnostics and pharmaceuticals , announce the formation of a joint venture to develop , manufacture and commercialize two of OPKO Health , Inc. 's clinical stage , long-acting drug products in Greater China and eight other Asian territories . | 1 | |
8/12/2020 | Client | ||||
6/24/2020 | Client |
Date | 2/15/2022 | 9/24/2021 | 9/14/2021 | 8/12/2020 | 6/24/2020 |
---|---|---|---|---|---|
Type | Licensee | Licensee | Licensee | Client | Client |
Business Partner | |||||
Country | United States | United States | United States | ||
News Snippet | In 2014 , Pfizer and OPKO Health , Inc. entered into a worldwide agreement for the development and commercialization of NGENLA for the treatment of GHD . | In 2014 , Pfizer and OPKO Health , Inc. entered into a worldwide agreement for the development and commercialization of somatrogon for the treatment of GHD . | SHANGHAI and MIAMI , Sept. 14 , 2021 -- LeaderMed Group , a pharmaceutical development company with operations based in Asia , and OPKO Health , Inc. , a diversified healthcare company focused on diagnostics and pharmaceuticals , announce the formation of a joint venture to develop , manufacture and commercialize two of OPKO Health , Inc. 's clinical stage , long-acting drug products in Greater China and eight other Asian territories . | ||
Sources | 2 | 2 | 1 |
OPKO Health Team
11 Team Members
OPKO Health has 11 team members, including , .
Name | Work History | Title | Status |
---|---|---|---|
Michael Tolentino | Regeneron Pharmaceuticals, University of Pennsylvania, Harvard University, University of Massachusetts Medical School, National Eye Institute, and Brown University | Founder | Current |
Name | Michael Tolentino | ||||
---|---|---|---|---|---|
Work History | Regeneron Pharmaceuticals, University of Pennsylvania, Harvard University, University of Massachusetts Medical School, National Eye Institute, and Brown University | ||||
Title | Founder | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.